Back to News
Market Impact: 0.3
Immunology Drugmaker Electra Opens Flat After Upsized US IPO
Source: Bloomberg
IPOs & SPACsHealthcare & BiotechCapital Markets
Electra Therapeutics raised $350 million in an upsized U.S. IPO, but its shares opened Friday at the IPO price, indicating muted immediate trading demand. The successful enlarged offering provides meaningful funding for the clinical-stage immunology drug developer, though the flat debut limits the near-term positive market signal.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Japan has record 100,000 people aged over 100: How societies are ageing
- Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal
- ProEnergy eyes $40 billion to $50 billion valuation in US IPO
- Anthropic delays IPO staging to November amid AI fears, WSJ says
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuters